Predicting type 1 diabetes using biomarkers

Diabetes Care

Volumn 38, Issue 6, 2015, Pages 989-996

  Bonifacio, Ezio ^a  

^a CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; HLA DQ ANTIGEN; HLA DQ8 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; HLA DRB1 ANTIGEN; INSULIN ANTIBODY; PANCREAS ISLET CELL ANTIBODY; AUTOANTIBODY;

AGE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CELL DEATH; CELL STRESS; CHEMOLUMINESCENCE; DIAGNOSTIC ACCURACY; DISEASE COURSE; DYSGLYCEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; GENE LOCUS; GENETIC RISK; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; METABOLOMICS; PANCREAS ISLET BETA CELL; PREDICTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TRANSCRIPTOMICS; BLOOD; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNOLOGY; INFANT; MALE; ONSET AGE; PANCREAS ISLET; PROGNOSIS; RISK FACTOR;

AGE OF ONSET; AUTOANTIBODIES; AUTOIMMUNITY; BIOMARKERS; CHILD; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERGLYCEMIA; INFANT; ISLETS OF LANGERHANS; MALE; PROGNOSIS; RISK FACTORS;

EID: 84951022849     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0101     Document Type: Article

References (55)

1. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS 2010;5:463-466.
2. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983;222: 1337-1339.
3. Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64K autoantigen in insulindependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990;347:151-156.
4. Rabin DU, Pleasic SM, Shapiro JA, et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 1994;152:3183-3188.
5. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-17045.
6. Ziegler A-G, Bonifacio E; BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 2012;55:1937-1943.
7. Parikka V, Nanẗo-Salonen K, Saarinen M, et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012;55: 1926-1936.
8. Krischer JP, Lynch KF, Schatz DA, et al. the TEDDY Study Group. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: The TEDDY study. Diabetologia. 10 February 2015 [Epub ahead of print].
9. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473-2479.
10. Gorsuch AN, Spencer KM, Lister J, et al. Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981;2:1363-1365.
11. Bonifacio E, Krumsiek J, Winkler C, Theis FJ, Ziegler AG. A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion. Acta Diabetol 2014;51: 403-411.
12. Ziegler A-G, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity 2010;32:468-478.
13. Lambert AP, Gillespie KM, Thomson G, et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 2004;89: 4037-4043.
14. Nanẗo-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a doubleblind, randomised controlled trial. Lancet 2008; 372:1746-1755.
15. Knip M, °Akerblom HK, Becker D, et al.; TRIGR Study Group. Hydrolyzed infant formula and early b-cell autoimmunity: a randomized clinical trial. JAMA 2014;311:2279-2287.
16. Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004;364:1699- 1700.
17. Barrett JC, Clayton DG, Concannon P, et al.; Type 1 Diabetes Genetics Consortium. Genomewide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009;41:703-707.
18. Clayton DG. Prediction and interaction in complex disease genetics: experience in type 1 diabetes. PLoS Genet 2009;5:e1000540.
19. Winkler C, Krumsiek J, Buettner F, et al. Feature ranking of type 1 diabetes susceptibility genes improves prediction of type 1 diabetes. Diabetologia 2014;57:2521-2529.
20. Cardwell CR, Stene LC, Joner G, et al. Birthweight and the risk of childhood-onset type 1 diabetes: a meta-analysis of observational studies using individual patient data. Diabetologia 2010;53:641-651.
21. Cardwell CR, Stene LC, Joner G, et al. Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 2008;51:726-735.
22. Bonifacio E, Warncke K, Winkler C, Wallner M, Ziegler AG. Cesarean section and interferoninduced helicase gene polymorphisms combineto increase childhood type 1 diabetes risk. Diabetes 2011;60:3300-3306.
23. Heninger AK, Monti P, Wilhelm C, et al. Activation of islet autoreactive näive T cells in infants is influenced by homeostatic mechanisms and antigen-presenting capacity. Diabetes 2013;62:2059-2066.
24. Eugster A, Lindner A, Heninger A-K, et al. Measuring T cell receptor and T cell gene expression diversity in antigen-responsive human CD41 T cells. J Immunol Methods 2013;400-401:13-22.
25. Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK. Proinsulin/Insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 2013;36:2266-2270.
26. Miao D, Guyer KM, Dong F, et al. GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes 2013;62:4174-4178.
27. Torn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51:846-852.
28. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004;114: 589-597.
29. Mayr A, Schlosser M, Grober N, et al. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 2007;56:1527-1533.
30. Bonifacio E, Bingley PJ, Shattock M, et al. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 1990;335:147-149.
31. Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004;53:384-392.
32. Sosenko JM, Skyler JS, Palmer JP, et al.; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 2013;36: 2615-2620.
33. Bonifacio E, Scirpoli M, Kredel K, Fuchtenbusch M, Ziegler AG. Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol 1999;163:525-532.
34. Sosenko JM, Skyler JS, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-Type 1. Diabetes 2012; 61:1331-1337.
35. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al.; Diabetes Prevention Trial-Type 1 Study Group. Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:1603-1607.
36. Krischer JP; Type 1 Diabetes TrialNet Study Group. The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 2013;56:1919-1924.
37. Helminen O, Aspholm S, Pokka T, et al. HbA1c predicts time to diagnosis of type 1 diabetes in children at risk. Diabetes 2015;64: 1719-1727.
38. Elding Larsson H, Vehik K, Bell R, et al.; TEDDY Study Group; SEARCH Study Group; Swediabkids Study Group; DPV Study Group; Finnish Diabetes Registry Study Group. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 2011; 34:2347-2352.
39. Roep BO. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia 2003;46:305-321.
40. Velthuis JH, Unger WW, Abreu JRF, et al. Simultaneous detection of circulating autoreactive CD81 T-cells specific for different islet cellassociated epitopes using combinatorial MHC multimers. Diabetes 2010;59:1721-1730.
41. Gratama JW, Boeckh M, Nakamura R, et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010; 116:1655-1662.
42. Remmerswaal EBM, Klarenbeek PL, Alves NL, et al. Clonal evolution of CD81 T cell responses against latent viruses: relationship among phenotype, localization, and function. J Virol 2015;89:568-580.
43. Nguyen THO, Rowntree LC, Pellicci DG, et al. Recognition of distinct cross-reactive virus-specific CD81 T cells reveals a unique TCR signature in a clinical setting. J Immunol 2014;192:5039-5049.
44. Akirav EM, Lebastchi J, Galvan EM, et al. Detection of b cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A 2011;108:19018-19023.
45. Jiang L, Brackeva B, Ling Z, et al. Potential of protein phosphatase inhibitor 1 as biomarker of pancreatic b-cell injury in vitro and in vivo. Diabetes 2013;62:2683-2688.
46. Habib T, Funk A, Rieck M, et al. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol 2012;188:487-496.
47. Ferreira RC, Guo H, Coulson RMR, et al. A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes 2014;63: 2538-2550.
48. Kallionpäa H, Elo LL, Laajala E, et al. Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility. Diabetes 2014;63:2402- 2414.
49. Oresic M, Simell S, Sysi-Aho M, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008;205:2975-2984.
50. Pflueger M, Seppanen-Laakso T, Suortti T, et al. Age- And islet autoimmunity-associated differences in amino acid and lipid metabolites in children at risk for type 1 diabetes. Diabetes 2011;60:2740-2747.
51. Zhang Q, Fillmore TL, Schepmoes AA, et al. Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes. J Exp Med 2013;210:191-203.
52. Moulder R, Bhosale SD, Erkkila T, et al. Serum proteomes distinguish children developing type 1 diabetes in a cohort with HLA-conferred susceptibility. Diabetes 2015;64:2265-2278.
53. Rakyan VK, Beyan H, Down TA, et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet 2011;7:e1002300.
54. Bingley PJ, Gale EAM; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: The role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006;49: 881-890.
55. Hawa MI, Kolb H, Schloot N, et al.; Action LADA Consortium. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013;36:908-913.